Antitumor Effect of Metformin in Combination with Binimetinib on Melanoma Cells
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Cutaneous melanoma is a fatal disease for patients with distant metastasis. Metformin is the most widely used anti-diabetic drug, and proved to suppress cell proliferation and metastasis in diverse cancers including melanoma. We previously reported that MEK inhibitor trametinib increases the expression of epithelial-mesenchymal transition (EMT) regulators and melanoma cell motility, which are suppressed by addition of metformin in A375 melanoma cells. To confirm our findings further, we first evaluated the effect of metformin in combination with another MEK inhibitor binimetinib on cell viability in G361 melanoma cells. We then investigated whether binimetinib affects the expression of EMT regulators and cell motility. We finally monitored the effect of metformin on binimetinib-induced cell migration. Cell viability assay showed that combination index (CI) value at ED50 is 0.80, suggesting synergy for the combination of metformin with binimetinib. Our results also revealed that binimetinib increased the expression of EMT regulators such as integrin αV, fibronectin and slug, which correlate well with the enhanced cell migration in wound healing assay. Metformin, on the contrary, suppressed the expression of sparc, integrin αV, fibronectin and N-cadherin with the reduced cell motility. The combination treatment showed that metformin counteracts the binimetinib-induced increase of cell motility. Overall, these results suggest that metformin with binimetinib might be useful as a potential therapeutic adjuvant against cell survival and metastatic activity in melanoma patients.
Abstract
Cutaneous melanoma is a fatal disease for patients with distant metastasis. Metformin is the most widely used anti-diabetic drug, and proved to suppress cell proliferation and metastasis in diverse cancers including melanoma. We previously reported that MEK inhibitor trametinib increases the expression of epithelial-mesenchymal transition (EMT) regulators and melanoma cell motility, which are suppressed by addition of metformin in A375 melanoma cells. To confirm our findings further, we first evaluated the effect of metformin in combination with another MEK inhibitor binimetinib on cell viability in G361 melanoma cells. We then investigated whether binimetinib affects the expression of EMT regulators and cell motility. We finally monitored the effect of metformin on binimetinib-induced cell migration. Cell viability assay showed that combination index (CI) value at ED50 is 0.80, suggesting synergy for the combination of metformin with binimetinib. Our results also revealed that binimetinib increased the expression of EMT regulators such as integrin αV, fibronectin and slug, which correlate well with the enhanced cell migration in wound healing assay. Metformin, on the contrary, suppressed the expression of sparc, integrin αV, fibronectin and N-cadherin with the reduced cell motility. The combination treatment showed that metformin counteracts the binimetinib-induced increase of cell motility. Overall, these results suggest that metformin with binimetinib might be useful as a potential therapeutic adjuvant against cell survival and metastatic activity in melanoma patients.
참고문헌 (30)
- Alexandrov LB, "Signatures of mutational processes in human cancer", Nature, 500, pp.415~421 (2013)
- "Cancer facts & figures 2020" (2020)[URL]
- Bowker SL, "Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin", Diabetes Care, 29, pp.254~258 (2006)
- Cerezo M, "Metformin blocks melanoma invasion and metastasis development in AMPK", p53-dependent manner, 2013, pp.12, 1605~1615
- Chou TC, "Generalized equations for the analysis of inhibitions of MichaelisMenten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors", Eur J Biochem, 115, pp.207~216 (1981)
- Della Corte CM, "Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells", Oncotarget, 7, pp.4265~4278 (2016)
- Domingues B, "Melanoma treatment in review", ImmunoTargets Ther, 7, pp.35~49 (2018)
- Evans JMM, "Metformin and reduced risk of cancer in diabetic patients", Br Med J, 330, pp.1304~1305 (2005)
- Ferlay J, "Estimating the global cancer incidence and mortality in 2018 : GLOBOCAN sources and methods", Int J Cancer, 144, pp.1941~1953 (2019)
- Goyal G, "Systemic therapy in metastatic melanoma", Fed Pract, 32, pp.57S~65S (2015)
- Holderfield M, "Targeting RAF kinases for cancer therapy : BRAF-mutated melanoma and beyond", Nat Rev Cancer, 14, pp.455~467 (2014)
- Eunjeong Ko, "Antitumor Activity of Combination Therapy with Metformin and Trametinib in Non-Small Cell Lung Cancer Cells", 발생과 생식, 24(2), pp.113~123 (2020), 한국발생생물학회
- Lee Y, "Effect of metformin in combination with trametinib and paclitaxel on cell survival and metastasis in melanoma cells", Anticancer Res, 41, pp.1387~1399 (2021)
- Leonardi GC, "Cutaneous melanoma : From pathogenesis to therapy(review)", Int J Oncol, 52, pp.1071~1080 (2018)
- Long GV, "Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib", J Clin Oncol, 36, pp.667~673 (2018)
- Long GV, "Increased MAPK reactivation in early resistance to dabrafenib", trametinib combination therapy of BRAF-mutant metastatic melanoma, 2014, pp.5, 5694~
- Martin MJ, "Metformin accelerates the growth of BRAFV600E-driven melanoma by upregulating VEGF-A", Cancer Discov, 2, pp.344~355 (2012)
- Morgillo F, "Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines", Clin Cancer Res, 19, pp.3508~3519 (2013)
- Niehr F, "Combination therapy with vemurafenib(PLX4032", RG7204)and metformin in melanoma cell lines with distinct driver mutations, 2011, pp.9, 76~
- Ryabaya O, "Metformin increases antitumor activity of MEK inhibitor binimetinib in 2D and 3D models of human metastatic melanoma cells", Biomed Pharmacother, 109, pp.2548~2560 (2019)
- Scherbakov AM, "The phenomenon of acquired resistance to metformin in breast cancer cells : The interaction of growth pathways and estrogen receptor signaling", IUBMB Life, 68, pp.281~292 (2016)
- Shaw RJ, "The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin", Science, 310, pp.1642~1646 (2005)
- Smalley KS, "PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma", Curr Opin Invest Drugs, 11, pp.699~706 (2010)
- Tseng HW, "Metformin treatment suppresses melanoma cell growth and modulation of microRNA expression", Cancers, 11, pp.209~ (2019)
- Vancura A, "Metformin as an anticancer agent", Trends Pharmacol Sci, 39, pp.867~878 (2018)
- Vujic I, "Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer", Oncotarget, 6, pp.969~978 (2015)
- Vultur A, "MEK inhibition affects STAT3signaling and invasion in human melanoma cell lines", Oncogene, 33, pp.1850~1861 (2014)
- Welsh SJ, "Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?", Eur J Cancer, 62, pp.76~85 (2016)
- Woodard J, "AMP-activated kinase(AMPK)-generated signals in malignant melanoma cell growth and survival", Biochem Biophys Res Commun, 398, pp.135~139 (2010)
- Zhao Y, "MEK inhibitor, PD98059, promotes breast cancer cell migration by inducing β-catenin nuclear accumulation", Oncol Rep, 38, pp.3055~3063 (2017)